News

Helperby also presented preclinical data which shows that AZT is active against carbapenem and colistin resistant Enterobacteriaceae. AZT is a DNA chain terminator and represents a new class

This investment brings the total Tmunity Series A financing to $135 million. Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell

The rare disease drug maker revealed that the Japanese pharma company made three offers recently. Takeda’s latest offer came on 13 April, which was £46.50 per each share

The company has raised the funding from new and existing investors at a pre-money valuation of $2bn in the financing round of the AI pharmaceutical sector. From 2013, BenevolentAI

The approval is based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress. AstraZeneca oncology business unit

The collaboration brings together Sandoz expertise in launching and commercializing treatments with Pear's leading experience in digital therapeutics design and implementation. Sandoz and Pear will work together to

The German pharma major, which has been looking at various options for the consumer health business since last September, will use the sale proceeds mainly to reduce its

Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is said to be a prophylactic (preventative) treatment that can be administered by an injection of a

Catabasis is prioritizing this program to deliver against its goal of bringing a life changing therapy to those affected by Duchenne. Catabasis CEO Jill Milne said: “This decision